Industry

Biopharma

Research, clinical and manufacturing data grows faster than any team can govern it. Congruity360 gives biopharma organizations visibility and control over unstructured data – protecting IP, satisfying regulators and reducing what you store.

Request a Demo

10+ yrs

Typical retention window for clinical and regulatory records

60–80%

Of research and operational data is redundant, obsolete or trivial

30%+

Annual growth in unstructured scientific and manufacturing data

PB scale

Instrument, imaging and sequencing output across sites

Industry Challenges

Science moves fast. Data governance rarely keeps up.

Biopharma organizations carry decades of regulated, high-value data across labs, partners and acquisitions – most of it unclassified and unowned.

01

Research Data Sprawl

Instrument output, imaging, sequencing files and lab notebooks accumulate across labs, sites and clouds with no shared inventory or ownership.

02

Validated & Regulated Records

GxP, 21 CFR Part 11, HIPAA and EMA requirements demand defensible retention and audit evidence for content that often sits in ungoverned file shares.

03

Intellectual Property Exposure

Formulations, trial data and partner content are among the most targeted assets in the industry, yet permissions are frequently broad and unreviewed.

04

M&A and Partner Data

Acquisitions, CRO and CDMO relationships bring inherited data estates with unknown contents, unclear obligations and duplicated records.

The Solution

Turn a regulated data estate into
a governed advantage

Congruity360 gives biopharma teams the visibility, context and control to act on unstructured data across research, clinical, manufacturing and corporate environments.

Step 01

Discover

Inventory research, clinical, manufacturing and corporate data across labs, on-premises storage and cloud.

Step 02

Classify

Identify PHI, trial data, IP and GxP records – plus the stale and duplicate content that adds only cost and risk.

Step 03

Control

Tighten access to sensitive science and partner content, and isolate or remediate high-risk data.

Step 04

Govern

Apply retention, legal hold and disposition policies continuously, with evidence auditors and regulators accept.

Business Outcomes

What biopharma teams gain from
governed unstructured data

Less data in scope

Defensible reduction

Retire expired studies and duplicate instrument output so there is less to store, secure and produce.

Protected IP

Lower exposure

Find where formulations, trial data and partner content live and correct over-broad access.

Days, not months

Audit readiness

Answer inspection, legal hold and regulatory requests from a classified, searchable estate.

Lower storage spend

Optimized infrastructure

Tier or remove cold research data instead of buying capacity for content nobody uses.

AI-ready science

Trusted data for research AI

Give discovery and analytics teams curated, governed data sets instead of raw file shares.

Repeatable

Sustained governance

Keep policy applied as new studies, sites and acquisitions bring more data into the estate.

Customer Story

Pharmaceutical Inc.
secures data and reduces risk

Biopharma

Pharmaceutical Company cleaned up open access, enforced retention schedules and eliminated ROT data

Reduced infrastructure and backup costs, remediated open access issues and built an extensible governance foundation across cloud and on-prem environments.

Read the story
Pharmaceutical laboratory

Pharmaceutical Inc.

Data Security & Records Management

Ready to Take Control of
Your Biopharma Data?

Start with a data assessment and see exactly what lives across your research, clinical and manufacturing environments.